Volume 137, Issue 4, Pages 1250-1260 (October 2009) Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab  William J. Sandborn, Paul Rutgeerts, Brian G. Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Jiandong Lu, Kevin Horgan, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J.S. de Villiers, Daniel Present, Bruce E. Sands, Jean Frédéric Colombel  Gastroenterology  Volume 137, Issue 4, Pages 1250-1260 (October 2009) DOI: 10.1053/j.gastro.2009.06.061 Copyright © 2009 AGA Institute Terms and Conditions

Figure 1 Enrollment and treatment of patients in the ACT-1 and -2 trials. Data sources for colectomy follow-up through 54 weeks include ACT-1, ACT-2, ACT-2 extension, RESULTS-UC, and retrospective data collection. Gastroenterology 2009 137, 1250-1260DOI: (10.1053/j.gastro.2009.06.061) Copyright © 2009 AGA Institute Terms and Conditions

Figure 2 (A) Kaplan–Meier estimate of the proportion of patients free of colectomy through 54 weeks for the placebo and combined infliximab groups in ACT-1 and -2. (B) Summary of hazard ratios by subgroup for time to colectomy through 54 weeks after the first infusion in ACT-1 and -2. The vertical solid line represents the treatment effect for the overall population. CI, confidence interval; NAP, not applicable; UC, ulcerative colitis; 5-ASA, 5-aminosalicylates; 6-MP, 6-mercaptopurine. (C) Summary of hazard ratios by treatment group and by study for time to colectomy or commercial infliximab use through 54 weeks after the first infusion in ACT-1 and -2. Gastroenterology 2009 137, 1250-1260DOI: (10.1053/j.gastro.2009.06.061) Copyright © 2009 AGA Institute Terms and Conditions